Drugs /
afatinib
Overview
Biomarker-Directed Therapies
Clinical Trials
Afatinib has been investigated in 37 clinical trials, of which 31 are open and 6 are closed. Of the trials investigating afatinib, 7 are phase 1 (5 open), 4 are phase 1/phase 2 (3 open), 24 are phase 2 (21 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 4 (1 open).
EGFR A763_Y764insFQEA, EGFR Exon 19 Deletion, and EGFR Exon 19 Insertion are the most frequent biomarker inclusion criteria for afatinib clinical trials.
Non-small cell lung carcinoma, malignant solid tumor, and adenocarcinoma of the gastroesophageal junction are the most common diseases being investigated in afatinib clinical trials [2].
Drug Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.